Ascentage Pharma Group International Management

Management Kriterienprüfungen 2/4

Ascentage Pharma Group International's CEO ist Dajun Yang, ernannt in Jan 2009, hat eine Amtszeit von 15.33 Jahren. Die jährliche Gesamtvergütung beträgt CN¥4.78M, bestehend aus 94.7% Gehalt und 5.3% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.027% der Aktien des Unternehmens, im Wert von HK$1.40M. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 5.5 Jahre bzw. 4.9 Jahre.

Wichtige Informationen

Dajun Yang

Geschäftsführender

CN¥4.8m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	94.7%
Amtszeit als Geschäftsführer	15.5yrs
Eigentum des Geschäftsführers	0.02%
Durchschnittliche Amtszeit des Managements	5.7yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.1yrs

Jüngste Management Updates

Here's Why Ascentage Pharma Group International's (HKG:6855) CEO May Not Expect A Pay Rise This Year

May 03

Recent updates

Ascentage Pharma Group International's (HKG:6855) Shares Climb 29% But Its Business Is Yet to Catch Up

Jun 18

Here's Why Ascentage Pharma Group International's (HKG:6855) CEO May Not Expect A Pay Rise This Year

May 03

Why We're Not Concerned Yet About Ascentage Pharma Group International's (HKG:6855) 30% Share Price Plunge

Mar 30

Are Investors Undervaluing Ascentage Pharma Group International (HKG:6855) By 40%?

Feb 17

There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Dec 20

Ascentage Pharma Group International (HKG:6855) Is Making Moderate Use Of Debt

Oct 28

Some Analysts Just Cut Their Ascentage Pharma Group International (HKG:6855) Estimates

Aug 27

There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Aug 23

Ascentage Pharma Group International (HKG:6855) Is Carrying A Fair Bit Of Debt

Jun 19

Ascentage Pharma Group International (HKG:6855) Has Debt But No Earnings; Should You Worry?

Dec 04

Is Ascentage Pharma Group International (HKG:6855) A Risky Investment?

Aug 30

Does Ascentage Pharma Group International (HKG:6855) Have A Healthy Balance Sheet?

Oct 04

An Intrinsic Calculation For Ascentage Pharma Group International (HKG:6855) Suggests It's 39% Undervalued

Jul 05

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Dajun Yang im Vergleich zu den Einnahmen von Ascentage Pharma Group International verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Dec 31 2023	CN¥5m	CN¥5m	-CN¥926m
Sep 30 2023	n/a	n/a	-CN¥902m
Jun 30 2023	n/a	n/a	-CN¥879m
Mar 31 2023	n/a	n/a	-CN¥881m
Dec 31 2022	CN¥4m	CN¥4m	-CN¥883m
Sep 30 2022	n/a	n/a	-CN¥848m
Jun 30 2022	n/a	n/a	-CN¥812m
Mar 31 2022	n/a	n/a	-CN¥797m
Dec 31 2021	CN¥5m	CN¥5m	-CN¥782m
Sep 30 2021	n/a	n/a	-CN¥759m
Jun 30 2021	n/a	n/a	-CN¥735m
Mar 31 2021	n/a	n/a	-CN¥706m
Dec 31 2020	CN¥4m	CN¥4m	-CN¥678m
Sep 30 2020	n/a	n/a	-CN¥922m
Jun 30 2020	n/a	n/a	-CN¥1b
Mar 31 2020	n/a	n/a	-CN¥1b
Dec 31 2019	CN¥4m	CN¥3m	-CN¥1b

Vergütung im Vergleich zum Markt: DajunDie Gesamtvergütung ($USD660.10K) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Hong Kong ($USD490.97K).

Entschädigung vs. Einkommen: DajunDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Dajun Yang (61 yo)

15.5yrs

Amtszeit

CN¥4,781,000

Vergütung

Dr. Dajun Yang, M.D., Ph D Co-Founded Ascentage Pharma Group International in 2019 and serves as its Chairman and has been its Director since November 17, 2017 and serves as its CEO since July 2018. His...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Dajun Yang	Co-Founder	15.5yrs	CN¥4.78m	0.025% CN¥ 2.1m
Shaomeng Wang	Co-Founder	no data	CN¥1.17m	keine Daten
Ming Guo	Co-Founder	15.2yrs	keine Daten	keine Daten
Thomas Knapp	Senior VP & General Counsel	5.3yrs	keine Daten	keine Daten
Yifan Zhai	Chief Medical Officer	no data	keine Daten	0.041% CN¥ 3.4m
Douglas Fang	Senior Vice President of Preclinical Development	no data	keine Daten	keine Daten
Jianfeng Wen	Senior Vice President of Pharmaceutical Science	no data	keine Daten	keine Daten
Raymond Kmetz	Chief Business Officer	5.4yrs	keine Daten	keine Daten
Yifei Zhu	Chief Commercial Officer	1.3yrs	keine Daten	keine Daten
Cheung Ki Wong	Company Secretary	6yrs	keine Daten	keine Daten

5.7yrs

Durchschnittliche Betriebszugehörigkeit

61yo

Durchschnittliches Alter

Erfahrenes Management: Das Managementteam von 6855 ist erfahren und erfahren (durchschnittliche Amtszeit: 5.5 Jahre).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Dajun Yang	Co-Founder	6.7yrs	CN¥4.78m	0.025% CN¥ 2.1m
Shaomeng Wang	Co-Founder	6.7yrs	CN¥1.17m	keine Daten
Allen S. Lichter	Chairman of the Clinical Advisory Board	1.5yrs	keine Daten	keine Daten
Paul A. Bunn	Member of Clinical Advisory Board	no data	keine Daten	keine Daten
David Sidransky	Independent Non-Executive Director	3.3yrs	CN¥510.00k	keine Daten
Jedd D. Wolchok	Member of Clinical Advisory Board	3.3yrs	keine Daten	keine Daten
Arul M. Chinnaiyan	Member of Clinical Advisory Board	no data	keine Daten	keine Daten
Changqing Ye	Independent Non-Executive Director	5.1yrs	CN¥502.00k	keine Daten
Dazhong Lu	Non-Executive Director	6yrs	CN¥25.00k	keine Daten
Wei Ren	Independent Non-Executive Director	5.1yrs	CN¥502.00k	keine Daten
Asher A. Chanan-Khan	Member of Clinical Advisory Board	1.5yrs	keine Daten	keine Daten

5.1yrs

Durchschnittliche Betriebszugehörigkeit

60yo

Durchschnittliches Alter

Erfahrener Vorstand: 6855Die Vorstandsmitglieder gelten als erfahren (4.9 Jahre durchschnittliche Amtszeit).

Ascentage Pharma Group International Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Ascentage Pharma Group International Announces Board and Committee Changes

Here's Why Ascentage Pharma Group International's (HKG:6855) CEO May Not Expect A Pay Rise This Year

Ascentage Pharma Group International, Annual General Meeting, May 10, 2024

Co-Founder recently bought HK$159k worth of stock

High number of new directors

High number of new directors

Recent updates

New minor risk - Shareholder dilution

Ascentage Pharma Group International's (HKG:6855) Shares Climb 29% But Its Business Is Yet to Catch Up

Ascentage Pharma Announces Updated Results from Three Studies of Olverembatinib (HQP1351)

New minor risk - Share price stability

Ascentage Pharma Group International Announces Board and Committee Changes

Ascentage Pharma Releases Updated Clinical Data of olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3%

Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates in 2024 American Society of Clinical Oncology Annual Meeting

Here's Why Ascentage Pharma Group International's (HKG:6855) CEO May Not Expect A Pay Rise This Year

Consensus EPS estimates fall by 15%

Why We're Not Concerned Yet About Ascentage Pharma Group International's (HKG:6855) 30% Share Price Plunge

Ascentage Pharma Group International, Annual General Meeting, May 10, 2024

Full year 2023 earnings released: CN¥3.28 loss per share (vs CN¥3.35 loss in FY 2022)

Ascentage Pharma Group International to Report Fiscal Year 2023 Results on Mar 27, 2024

Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting

Are Investors Undervaluing Ascentage Pharma Group International (HKG:6855) By 40%?

Ascentage Pharma Receives Clearance from the US Food and Drug Administration to Initiate Global Registrational Phase III Trial of Olverembatinib (HQP1351) in Patients with Chronic-Phase Chronic Myeloid Leukemia

Ascentage Pharma Announces Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia (CML) Management from the National Comprehensive Cancer Network (NCCN)

There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Ascentage Pharma Group International Presents Preliminary Results from A Phase II Study of Novel Drug Candidate, Olverembatinib

Ascentage Pharma Group International Releases the First Dataset of BCL-2 Inhibitor Lisaftoclax in Patients with R/R Mm, Demonstrating Encouraging ORR and VGPR

Ascentage Pharma Announces the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication

China National Medical Products Administration Approves Olverembatinib for Treatment of Cml-Cp Patients

Ascentage Pharma Group International to Present Results from Multiple Clinical Studies of olverembatinib and APG-2575 at the 2023 American Society of Hematology(ASH) Annual Meeting, two of which have been Selected for Oral Reports

Ascentage Pharma Group International (HKG:6855) Is Making Moderate Use Of Debt

Ascentage Pharma Releases Latest Data of Pelcitoclax (Apg-1252) Combined with Osimertinib Demonstrates Potential as A New Treatment Option for Tp53-And Egfr-Mutant Nsclc

Ascentage Pharma Announces First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naïve Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia

Ascentage Pharma Announces Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment Naïve Patients with CLL/SLL Approved by the China CDE

Consensus revenue estimates fall by 12%

Some Analysts Just Cut Their Ascentage Pharma Group International (HKG:6855) Estimates

First half 2023 earnings released: CN¥1.47 loss per share (vs CN¥1.54 loss in 1H 2022)

There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Ascentage Pharma Announces Clearance for Global Registrational Phase III Trial

Ascentage Pharma Group International to Report First Half, 2023 Results on Aug 21, 2023

Ascentage Pharma Group International Receives Clearance from the U.S. Food and Drug Administration to Initiate A Phase 3 Registrational Trial of Lisaftoclax

Ascentage Pharma Group International Announces CDE's Approval for the Phase III Pivotal Study in China of Olverembatinib for the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ All)

Ascentage Pharma Group International (HKG:6855) Is Carrying A Fair Bit Of Debt

Ascentage Pharma Group International Releases Updated Data Showing APG-2449's Potential as a New Treatment for Drug-Resistant NSCLC

Ascentage Pharma Group International Recommends Breakthrough Therapy Designation in China for the Treatment of Sdh-Deficient GIST

Ascentage Pharma Group International Presents Results from Four Studies at 2023 American Society of Clinical Oncology Annual Meeting

Consensus revenue estimates decrease by 22%, EPS upgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ascentage Pharma Group International has completed a Follow-on Equity Offering in the amount of HKD 550.125 million.

Ascentage Pharma Group International's Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List

Ascentage Pharma Group International Releases Preliminary Results from a Global Phase II Study of Lisaftoclax

Ascentage Pharma Delivers Oral Report on the First Dataset from the US Study of Olverembatinib (HQP1351) with Promising Efficacy Observed in Patients Who Failed Prior Treatment with Ponatinib

Ascentage Pharma Group International (HKG:6855) Has Debt But No Earnings; Should You Worry?

Ascentage Pharma's Global Industrial Base Obtains Drug Production Enterprise License

Ascentage Pharma Group International Announces IND Approval in China for Phase I Study of APG-5918 in Patients with Advanced Solid Tumors or Hematologic Malignancies

Ascentage Pharma Group International Announces Released Results from A Phase I Study of the Investigational Inhibitor of Apoptosis Protein (Iap) Antagonist Apg-1387 in Chinese Patients with Chronic Hepatitis B

Ascentage Pharma Releases Phase I Results of Iap Antagonist Apg-1387 in an Oral Report Showing Potential for Functionally Curing Chb

Co-Founder recently bought HK$159k worth of stock

Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, At the ASH Annual Meeting

Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting

Ascentage Pharma Announces Phase I/Ii Data of Olverembatinib (Hqp1351) Published in the Journal of Hematology & Oncology, Further Validating the Drug's Best-In-Class Potential

Is Ascentage Pharma Group International (HKG:6855) A Risky Investment?

First half 2022 earnings released: CN¥1.54 loss per share (vs CN¥1.53 loss in 1H 2021)

Ascentage Pharma Group International to Report Q2, 2022 Results on Aug 26, 2022

High number of new directors

Ascentage Pharma Announces Clinical Trial Application for Olverembatinib (HQP1351) Approved in Canada

Ascentage Pharma Announces China National Medical Products Administration Accepts and Grants Priority Review Designation to Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML

Ascentage Pharma Group International Announces Ind Clearance by the Us Fda for First-In-Human Study of Novel Eed Inhibitor Apg-5918

Ascentage Pharma Group International Releases Results from A Phase I Study of the Company's Novel Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575) in Chinese Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R Nhl) at the 2022 European Hematology Association Hybrid Congress

Ascentage Pharma Releases Updated Data Demonstrating Lisaftoclax's (APG-2575) Therapeutic Potential in Patients with R/R CLL/SLL

Ascentage Pharma Releases for the First Time Results of its FAK/ALK/ROS1 inhibitor APG-2449 Demonstrating Safety and Efficacy in Patients with Advanced NSCLC

Ascentage Pharma Group International Releases the Updated Results from A Phase II Study of the Mdm2-P53 Inhibitor Alrizomadlin (APG-115) Plus Pembrolizumab in Adults and Children with Various Solid Tumors in A Poster Discussion Session At the ASCO Annual Meeting

Ascentage Pharma Presents Updated Results from Multiple Clinical Studies Demonstrating Rapid Progress in Global Clinical Development

High number of new directors

Ascentage Pharma Group to Present Latest Clinical Data of Bcl-2 Inhibitorlisaftoclax (Apg-2575) in Patients with Relapsed/Refractory Non-Hodgkinlymphomas At 2022 European Hematology Association Hybrid Congress

Ascentage Pharma Group International Announces Management Changes, Effective May 20, 2022